How Pericarditis Treatment Evolved From Surgery to Targeted Biologics
A sweep from ancient Greece to IL-1 inhibitors reveals how pericarditis care became mechanism-driven and increasingly personalized.
Summary
Pericarditis — inflammation of the sac surrounding the heart — has been recognized since antiquity, but its treatment has transformed dramatically over the past century. This review in Circulation traces that evolution, from early surgical options like pericardiectomy to the mid-20th century introduction of NSAIDs and corticosteroids, which improved symptoms but left recurrence rates unacceptably high. Colchicine, validated in randomized trials, became a cornerstone therapy. The most significant recent advance is the recognition that recurrent pericarditis often has an autoinflammatory basis, opening the door to interleukin-1 inhibitors — anakinra and rilonacept — for refractory cases. Imaging advances, particularly cardiac MRI, now allow precise tissue characterization and risk stratification. Together, these shifts represent a move from empirical to personalized, mechanism-based care for a condition that affects heart function and quality of life across all adult age groups.
Detailed Summary
Pericarditis is one of the most common inflammatory cardiovascular conditions, accounting for a meaningful share of chest-pain presentations and emergency cardiology visits. For a longevity-focused audience, heart inflammation that triggers recurrence and potential constrictive complications represents a genuine threat to long-term cardiac function and healthspan. Understanding how its management has evolved helps clinicians and health-conscious individuals appreciate what modern, mechanism-driven care looks like in practice.
This narrative review, published in Circulation by Cleveland Clinic, Northwestern, Mayo Clinic, and international experts, traces the full arc of pericarditis history. Early descriptions by Hippocrates were refined in the 19th century by Laennec and later by influential clinicians such as Spodick and Hatle. Initial management was largely symptomatic or surgical — pericardiectomy addressed constrictive sequelae but carried significant risk.
The mid-20th century brought NSAIDs and corticosteroids, which controlled acute symptoms but were associated with high recurrence rates, particularly with steroid use. Echocardiography then revolutionized noninvasive diagnosis and enabled safer pericardiocentesis. More recently, cardiac MRI has added tissue-level characterization, improving risk stratification and guiding treatment duration decisions.
Randomized clinical trials established colchicine — an anti-inflammatory agent familiar from gout management — as a first-line adjunct that meaningfully reduces recurrence. The field's most transformative recent development is the recognition that recurrent pericarditis is frequently autoinflammatory rather than purely infectious or idiopathic. This mechanistic insight justified trials of interleukin-1 pathway inhibitors: anakinra (an IL-1 receptor antagonist) and rilonacept (an IL-1 trap) have demonstrated efficacy in refractory disease, with rilonacept receiving FDA approval for recurrent pericarditis.
The review authors see ongoing integration of advanced imaging, biomarker panels, and targeted immunomodulation as the path toward fully personalized pericardial care. Limitations include the narrative rather than systematic design and the restriction to abstract-level detail in this summary.
Key Findings
- Colchicine, validated in randomized trials, is now a cornerstone therapy that cuts pericarditis recurrence rates.
- Recurrent pericarditis is often autoinflammatory — IL-1 inhibitors anakinra and rilonacept are effective for refractory cases.
- Cardiac MRI now enables tissue characterization and risk stratification unavailable with echocardiography alone.
- Corticosteroids, once widely used, are associated with higher recurrence and should be used cautiously.
- The field has shifted from empirical, symptom-based management to mechanism-driven, personalized therapy.
Methodology
This is a narrative review article published in Circulation, synthesizing the historical and contemporary literature on pericarditis diagnosis and management. It does not employ systematic search or meta-analytic methods. Authors represent leading pericardial disease centers including Cleveland Clinic, Northwestern, Mayo Clinic, University of Udine, and the University of Athens.
Study Limitations
This is a narrative review without systematic search methodology, so selection bias in the literature cited is possible. Conflicts of interest exist: two senior authors have advisory relationships with Kiniksa Pharmaceuticals (maker of rilonacept) and other pericarditis-focused companies. This summary is based on the abstract only, as the full text is not open access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: